Maynard Um
-
-
-
-
-
-
-
Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $34 at H.C. Wainwright
-
-
-
-
-
-
-
TD Cowen on Biotechnology: '10+ Potential "Thome Run" Catalysts To Watch In 2026'
-
-
-
-
-
-
-
Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (AMLX): Grabar Law Office is Investigating Claims on Your Behalf as Securities Fraud Class Action Survives Motion to Dismiss
-
-
-
-
-
-
-
Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $12 at Mizuho
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Amylyx Pharmaceuticals inc. (AMLX)
-
-
-
-
-
-
-
Mizuho Upgrades Amylyx Pharmaceuticals inc. (AMLX) to Outperform
-
-
-
-
-
-
-
Goldman Sachs Reiterates Neutral Rating on Amylyx Pharmaceuticals inc. (AMLX)
-
396,355 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

